This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
by Zacks Equity Research
BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
BIIBNegative Net Change ILMNNegative Net Change IONSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
by Zacks Equity Research
DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down.
DYNNegative Net Change EXELPositive Net Change SRPTNegative Net Change KRYSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
by Zacks Equity Research
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
BIIBNegative Net Change EXELPositive Net Change KRYSNegative Net Change DNLINegative Net Change
biotechnology biotechs pharmaceuticals
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
by Zacks Equity Research
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
BIIBNegative Net Change LLYNegative Net Change ILMNNegative Net Change ATHAPositive Net Change
biotechs
Affimed Appoints New CEO, Shares Fall on Leadership Change
by Zacks Equity Research
AFMD appoints Shawn M. Leland as the company's new chief executive officer. Stock falls on the news.
RHHBYNegative Net Change ILMNNegative Net Change AFMDNegative Net Change FULCPositive Net Change
biotechs
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
by Zacks Equity Research
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
ILMNNegative Net Change KRYSNegative Net Change FULCPositive Net Change RXRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
by Zacks Equity Research
Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
GSKNegative Net Change PFENegative Net Change MRKPositive Net Change PCVXPositive Net Change
biotechs medical pharmaceuticals vaccines
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
by Zacks Equity Research
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
ILMNNegative Net Change NBIXNegative Net Change XENEPositive Net Change PRAXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates
by Zacks Equity Research
AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.
ILMNNegative Net Change KRYSNegative Net Change AMRXPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
by Kinjel Shah
BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.
BIIBNegative Net Change LLYNegative Net Change SAGENegative Net Change
biotechs pharmaceuticals
Viking Surges 342% in the Past Year: How Should You Play the Stock?
by Sundeep Ganoria
VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change MDGLNegative Net Change
biotechs medical pharmaceuticals
Terns Surges 29.6% in Three Months: Will the Momentum Continue?
by Zacks Equity Research
TERN has outperformed the industry in the past three months on encouraging pipeline progress of its candidates. Positive data on obesity candidates should boost the stock further.
NVSNegative Net Change EXELPositive Net Change KRYSNegative Net Change TERNNegative Net Change
biotechnology biotechs medical pharmaceuticals
ALNY Down Despite Positive Data From Heart Disease Drug Study
by Zacks Equity Research
Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.
ALNYPositive Net Change ILMNNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechs
Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.
SNYNegative Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
by Zacks Equity Research
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
ILMNNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
JNJNegative Net Change ARGXPositive Net Change FULCPositive Net Change BVSNegative Net Change
biotechs medical pharmaceuticals
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
by Zacks Equity Research
MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
AZNPositive Net Change MRKPositive Net Change FULCPositive Net Change BVSNegative Net Change
biotechs medical pharmaceuticals
EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication
by Zacks Equity Research
The FDA approves Emergent BioSolutions' sBLA seeking a label expansion of ACAM2000 for the mpox indication. Stock rises in pre-market trading.
ILMNNegative Net Change EBSPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechs
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
by Zacks Equity Research
The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.
GSKNegative Net Change PFENegative Net Change ILMNNegative Net Change MRNANegative Net Change
biotechs
SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas.
ILMNNegative Net Change KRYSNegative Net Change FULCPositive Net Change SWTXPositive Net Change
biotechs
Bull Of The Day: Bioventus (BVS)
by Brian Bolan
This stock has seen 3 consecutive beats of the Zacks Consensus Estimate and also posted solid margin expansion.
BVSNegative Net Change
biotechs hmo hospitals medical
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
by Zacks Equity Research
PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
PFENegative Net Change LLYNegative Net Change FULCPositive Net Change BVSNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
by Zacks Equity Research
VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Addex Stock Soars on Crucial Update From Indivior Research Deal
by Zacks Equity Research
ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.
JNJNegative Net Change FULCPositive Net Change ADXNNegative Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
by Zacks Equity Research
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.
ACADNegative Net Change SLNONegative Net Change FULCPositive Net Change BVSNegative Net Change
biotechnology biotechs medical pharmaceuticals